3D-assembly of interactive microgels to grow in vitro vascularized, structured, and beating human cardiac tissues in high-throughput
HEARTBEAT aims to create personalized, vascularized millimeter-scale heart tissues using innovative microgel assemblies to enhance stem cell interactions and mimic native environments.
Projectdetails
Introduction
Generating 3D in vitro functional tissues and organs in the millimeter scale remains an unmet dream of modern medicine. Irrespective of great efforts in the field of tissue engineering to design injectable/pipettable hydrogels or implantable/non-pipettable scaffolds for 3D cell growth, it is not yet possible to generate functional and personalized tissues with native-like structures and mature blood vessels.
Limitations of Current Materials
The main reason for this limitation is that current materials do not recapitulate the complexity and dynamics of the native cell environment. To create personalized human tissues, patient-derived induced pluripotent stem cells can differentiate into any cell type, but controlling stem cell expansion, differentiation, and organization inside the same 3D scaffold is not possible up to now. This control requires biomimetic and interactive materials beyond simple hydrogels.
Innovative Approach
HEARTBEAT will break with traditional ways to make 3D biomaterials by assembling and crosslinking a variety of unique pre-programmed, rod-shaped, and interactive microgels instead of molecular building blocks.
Main Aim
The main aim is to achieve macroporous, aligned, actuatable, and on-demand degradable constructs after automatically pipetting/mixing different microgels and cells, which is not possible with conventional hydrogels.
High-Throughput System
A compatible high-throughput system will be used to screen the innumerable combinations of design parameters to systematically study (stem)cell-material and cell-cell interactions to grow complex tissue.
Focus of the Project
In HEARTBEAT, I will focus on using the interactive bottom-up microgel assemblies to generate millimeter-scale vascularized beating heart tissues.
Research Goals
The project will elucidate how material properties, architectures, and actuation affect human heart tissue formation and vascularization and how the construct has to adapt to the growing tissue over time to provide the right extracellular environment.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 2.969.219 |
Totale projectbegroting | € 2.969.219 |
Tijdlijn
Startdatum | 1-10-2022 |
Einddatum | 30-9-2027 |
Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- DWI LEIBNIZ-INSTITUT FUR INTERAKTIVE MATERIALIEN EVpenvoerder
- RHEINISCH-WESTFAELISCHE TECHNISCHE HOCHSCHULE AACHEN
- UNIVERSITAETSKLINIKUM AACHEN
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Advanced human models of the heart to understand cardiovascular diseaseHeart2Beat aims to develop innovative 3D human cardiac models using microfluidic technology to enhance understanding and treatment of cardiovascular diseases through personalized medicine. | ERC Advanced... | € 2.500.000 | 2023 | Details |
Computationally and experimentallY BioEngineeRing the next generation of Growing HEARTsG-CYBERHEART aims to develop innovative experimental and computational methods for creating adaptable bioengineered hearts to improve treatment for congenital heart disease. | ERC Starting... | € 1.497.351 | 2022 | Details |
SUPRAmolecular Hydrogel Driven Assembly of Designer Heart TissuesThe SUPRAHEART project aims to develop synthetic squaramide-based hydrogels for scalable engineered heart tissues, enhancing reproducibility for pharmaceutical testing and commercialization. | ERC Proof of... | € 150.000 | 2025 | Details |
Nanorobotic microgels to control stem cell fateDeveloping innovative microgel technology with nanorobotics to enhance stem cell differentiation for improved cardiac regeneration in myocardial infarction patients. | ERC Starting... | € 1.500.000 | 2024 | Details |
Surgical optogenetic bioprinting of engineered cardiac muscleLIGHTHEART aims to revolutionize heart failure treatment by developing a surgical bioprinting tool that uses optogenetics to create engineered cardiac muscle directly at the patient's heart. | ERC Starting... | € 1.499.705 | 2023 | Details |
Advanced human models of the heart to understand cardiovascular disease
Heart2Beat aims to develop innovative 3D human cardiac models using microfluidic technology to enhance understanding and treatment of cardiovascular diseases through personalized medicine.
Computationally and experimentallY BioEngineeRing the next generation of Growing HEARTs
G-CYBERHEART aims to develop innovative experimental and computational methods for creating adaptable bioengineered hearts to improve treatment for congenital heart disease.
SUPRAmolecular Hydrogel Driven Assembly of Designer Heart Tissues
The SUPRAHEART project aims to develop synthetic squaramide-based hydrogels for scalable engineered heart tissues, enhancing reproducibility for pharmaceutical testing and commercialization.
Nanorobotic microgels to control stem cell fate
Developing innovative microgel technology with nanorobotics to enhance stem cell differentiation for improved cardiac regeneration in myocardial infarction patients.
Surgical optogenetic bioprinting of engineered cardiac muscle
LIGHTHEART aims to revolutionize heart failure treatment by developing a surgical bioprinting tool that uses optogenetics to create engineered cardiac muscle directly at the patient's heart.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Next Generation 3D Tissue Models: Bio-Hybrid Hierarchical Organoid-Synthetic Tissues (Bio-HhOST) Comprised of Live and Artificial Cells.Bio-HhOST aims to create bio-hybrid materials with living and artificial cells for dynamic communication, enhancing tissue modeling and reducing animal use in drug research. | EIC Pathfinder | € 1.225.468 | 2024 | Details |
Engineering a living human Mini-heart and a swimming Bio-robotThe project aims to develop advanced in vitro human cardiac models, including a vascularized mini-heart and a bio-robot, to better assess cardiotoxicity and improve understanding of cardiovascular disease. | EIC Pathfinder | € 4.475.946 | 2022 | Details |
Bringing 3D cardiac tissues to high throughput for drug discovery screensDeveloping a high-throughput 3D cardiac model using microfluidic technology to enhance drug discovery for cardiovascular disease by improving predictive accuracy and scalability. | EIC Transition | € 1.457.500 | 2023 | Details |
High-throughput ultrasound-based volumetric 3D printing for tissue engineeringSONOCRAFT aims to revolutionize myocardial cell construct bioprinting by combining rapid volumetric printing with ultrasonic manipulation to create functional cardiac models for drug testing and disease research. | EIC Pathfinder | € 2.999.625 | 2025 | Details |
building vascular networks and Blood-Brain-Barriers through a Biomimetic manufacturing Technology for the fabrication of Human tissues and ORgansTHOR aims to revolutionize tissue engineering by creating patient-specific, fully functional human tissues using bioinspired mini-robots, eliminating the need for organ transplants. | EIC Pathfinder | € 3.994.150 | 2023 | Details |
Next Generation 3D Tissue Models: Bio-Hybrid Hierarchical Organoid-Synthetic Tissues (Bio-HhOST) Comprised of Live and Artificial Cells.
Bio-HhOST aims to create bio-hybrid materials with living and artificial cells for dynamic communication, enhancing tissue modeling and reducing animal use in drug research.
Engineering a living human Mini-heart and a swimming Bio-robot
The project aims to develop advanced in vitro human cardiac models, including a vascularized mini-heart and a bio-robot, to better assess cardiotoxicity and improve understanding of cardiovascular disease.
Bringing 3D cardiac tissues to high throughput for drug discovery screens
Developing a high-throughput 3D cardiac model using microfluidic technology to enhance drug discovery for cardiovascular disease by improving predictive accuracy and scalability.
High-throughput ultrasound-based volumetric 3D printing for tissue engineering
SONOCRAFT aims to revolutionize myocardial cell construct bioprinting by combining rapid volumetric printing with ultrasonic manipulation to create functional cardiac models for drug testing and disease research.
building vascular networks and Blood-Brain-Barriers through a Biomimetic manufacturing Technology for the fabrication of Human tissues and ORgans
THOR aims to revolutionize tissue engineering by creating patient-specific, fully functional human tissues using bioinspired mini-robots, eliminating the need for organ transplants.